Antimicrobial resistant infections (AMR) are on the rise and pose a significant global risk. Developing countries, in particular, are vulnerable because they often lack key medical resources. The development of new antibacterial treatments is costly while the return on investment is low. Organized in cooperation with the World Health Organization (WHO), the conference will explore solutions to this dilemma, seeking to facilitate cooperation between biotech firms, potential investors and governments for AMR investment. It will present some innovative technologies that need financial support and provide a matchmaking platform to connect impact investors with researchers and developers of treatments against AMR.
Issues for the debate
- What is the role of governments?
- What are the needs of the industry?
- Which innovative means of investment can help address the AMR problem?